HBM BioCapital with a committed capital of $ 170 million is a Cayman Islands limited partnership investing in private companies in the emerging pharma, biotechnology, medical devices and diagnostics industries. HBM BioCapital usually invests between $5 million to $10 million. Larger transactions are shared with HBM BioVentures. Investors in HBM BioCapital are HBM BioVentures, larger institutional investors and pharma entrepreneurs.
|Delenex Therapeutics||5/2011||Series A||$19.3M||6|
|Delenex Therapeutics||11/2010||Series A||$14M||4|
|MTM Laboratories||10/2009||Series C||€39M||5|